Drug rash with eosinophilia and systemic symptoms (dress syndrome)

Cutis

Volumn 89, Issue 4, 2012, Pages 180-182

  Gordon, Justin S ^a   Neyman, Kimberly M ^a   Wells, Ryan D ^a   Chen, Suephy C ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; PREDNISONE; THIAZOLE DERIVATIVE; ZIPRASIDONE;

ADULT; BIPOLAR DISORDER; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG ERUPTION; DRUG HYPERSENSITIVITY; EOSINOPHILIA; FEMALE; HUMAN; LETTER; RISK FACTOR; SYNDROME; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG ERUPTIONS; DRUG HYPERSENSITIVITY; EOSINOPHILIA; FEMALE; HUMANS; PIPERAZINES; PREDNISONE; RISK FACTORS; SYNDROME; THIAZOLES; TREATMENT OUTCOME;

EID: 84863000462     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (15)

1. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug-induced hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). Semin Cutan Med Surg. 1996; 15: 250-257.
2. Seishima M, Yamanaka S, Fujisawa T, et al. Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome. Br J Dermatol. 2006; 155: 344-349.
3. Komatsuda A, Okamoto Y, Hatakeyama T, et al. Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus [published online ahead of print October 19, 2007]. Clin Rheumatol. 2008; 27: 395-397.
4. Descamps V, Mahe E, Houhou N, et al. Drug-induced hypersensitivity syndrome associated with Epstein-Barr virus infection. Br J Dermatol. 2003; 148: 1032-1034.
5. Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf. 1999; 21: 489-501.
6. Mansur AT, Yasar SP, Göktay F. Anticonvulsant hypersensitivity syndrome: clinical and laboratory features. Int J Dermatol. 2008; 47: 1184-1189.
7. Tsai CF, Tsai SJ, Hwang JP. Ziprasidone-induced hypersensitivity syndrome in an aged schizophrenia patient. Int J Geriatr Psychiatry. 2005; 20: 797-799.
8. Raz A, Bergman R, Eilam O, et al. A case report of olanzapine-induced hypersensitivity syndrome. Am J Med Sci. 2001; 321: 156-158.
9. Magro CM, Crowson AN, Mihm MC. The Cutaneous Lymphoid Proliferations: A Comprehensive Textbook of Lymphocytic Infiltrates of the Skin. Hoboken, NJ: Wiley-Liss; 2007.
10. Pincus LB, Grossman ME, Fox LP. The exanthem of dengue fever: clinical features of two US tourists traveling abroad [published online ahead of print October 24, 2007]. J Am Acad Dermatol. 2008; 58: 308-316.
11. Mackay-Wiggan JM, Cohen DJ, Hardy MA, et al. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol. 2003; 48: 55-60.
12. Friedman JS, Fulghum Walters R, Woosley J, et al. A unique presentation of calcinosis cutis in a patient with cystic fibrosis after double lung transplants. J Am Acad Dermatol. 2003; 49: 1131-1136.
13. Yawalkar N, Pichler WJ. Immunohistology of drug-induced exanthema: clues to pathogenesis. Curr Opin Allergy Clin Immunol. 2001; 1: 299-303.
14. Botelho LF, Picosse FR, Padilha MH, et al. Acute generalized exanthematous pustulosis induced by cefepime: a case report. Case Rep Dermatol. 2010; 2: 82-87.
15. Gerson D, Sriganeshan V, Alexis JB. Cutaneous drug eruptions: a 5-year experience. J Am Acad Dermatol. 2008; 59: 995-999.